

Marius N Stan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3069912/publications.pdf>

Version: 2024-02-01

76
papers

5,570
citations

201575

27
h-index

155592

55
g-index

77
all docs

77
docs citations

77
times ranked

4581
citing authors

#	ARTICLE	IF	CITATIONS
1	2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. <i>Thyroid</i> , 2016, 26, 1343-1421.	2.4	1,757
2	Hyperthyroidism and Other Causes of Thyrotoxicosis: Management Guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. <i>Thyroid</i> , 2011, 21, 593-646.	2.4	771
3	Hyperthyroidism and Other Causes of Thyrotoxicosis: Management Guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. <i>Endocrine Practice</i> , 2011, 17, 456-520.	1.1	553
4	Subclinical Hypothyroidism in Pregnancy: A Systematic Review and Meta-Analysis. <i>Thyroid</i> , 2016, 26, 580-590.	2.4	277
5	Randomized Controlled Trial of Rituximab in Patients With Graves' Orbitopathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 432-441.	1.8	262
6	Comparative Effectiveness of Therapies for Graves' Hyperthyroidism: A Systematic Review and Network Meta-Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 3671-3677.	1.8	192
7	Risk Factors for Development or Deterioration of Graves' Ophthalmopathy. <i>Thyroid</i> , 2010, 20, 777-783.	2.4	171
8	Thyroid hormone treatment among pregnant women with subclinical hypothyroidism: US national assessment. <i>BMJ: British Medical Journal</i> , 2017, 356, i6865.	2.4	129
9	A stimulatory TSH receptor antibody enhances adipogenesis via phosphoinositide 3-kinase activation in orbital preadipocytes from patients with Graves' ophthalmopathy. <i>Journal of Molecular Endocrinology</i> , 2011, 46, 155-163.	1.1	126
10	MANAGEMENT OF ENDOCRINE DISEASE: Rituximab therapy for Graves' orbitopathy – lessons from randomized control trials. <i>European Journal of Endocrinology</i> , 2017, 176, R101-R109.	1.9	83
11	The Evaluation and Treatment of Graves Ophthalmopathy. <i>Medical Clinics of North America</i> , 2012, 96, 311-328.	1.1	72
12	Patterns of Use, Efficacy, and Safety of Treatment Options for Patients with Graves' Disease: A Nationwide Population-Based Study. <i>Thyroid</i> , 2020, 30, 357-364.	2.4	67
13	Randomized, Double-Blind, Placebo-Controlled Trial of Long-Acting Release Octreotide for Treatment of Graves' Ophthalmopathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 4817-4824.	1.8	62
14	Comparative Effectiveness of Treatment Choices for Graves' Hyperthyroidism: A Historical Cohort Study. <i>Thyroid</i> , 2017, 27, 497-505.	2.4	59
15	Cohort Study on Radioactive Iodine-Induced Hypothyroidism: Implications for Graves' Ophthalmopathy and Optimal Timing for Thyroid Hormone Assessment. <i>Thyroid</i> , 2013, 23, 620-625.	2.4	58
16	Clinical Presentation and Diagnostic Challenges of Thyroid Lymphoma: A Cohort Study. <i>Thyroid</i> , 2016, 26, 1061-1067.	2.4	57
17	Outcomes of Radiofrequency Ablation Therapy for Large Benign Thyroid Nodules: A Mayo Clinic Case Series. <i>Mayo Clinic Proceedings</i> , 2018, 93, 1018-1025.	1.4	57
18	Current and Emerging Treatment Strategies for Graves' Orbitopathy. <i>Drugs</i> , 2019, 79, 109-124.	4.9	56

#	ARTICLE	IF	CITATIONS
19	Effects of Levothyroxine Therapy on Pregnancy Outcomes in Women with Subclinical Hypothyroidism. <i>Thyroid</i> , 2016, 26, 980-986.	2.4	53
20	Thyrotoxicosis: Diagnosis and Management. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1048-1064.	1.4	52
21	Development and Pilot Testing of an Encounter Tool for Shared Decision Making About the Treatment of Graves' Disease. <i>Thyroid</i> , 2015, 25, 1191-1198.	2.4	45
22	Body mass index and the development of amiodarone-induced thyrotoxicosis in adults with congenital heart disease—A cohort study. <i>International Journal of Cardiology</i> , 2013, 167, 821-826.	0.8	33
23	Riedel's thyroiditis association with IgG4-related disease. <i>Clinical Endocrinology</i> , 2017, 86, 425-430.	1.2	32
24	Ethanol Ablation for the Treatment of Cystic and Predominantly Cystic Thyroid Nodules. <i>Mayo Clinic Proceedings</i> , 2018, 93, 1009-1017.	1.4	31
25	Risk of Malignancy in Thyroid Nodules with Non-Diagnostic Fine-Needle Aspiration: A Retrospective Cohort Study. <i>Thyroid</i> , 2016, 26, 1598-1604.	2.4	28
26	Thyroidectomy for Amiodarone-Induced Thyrotoxicosis: Mayo Clinic Experience. <i>Journal of the Endocrine Society</i> , 2018, 2, 1226-1235.	0.1	28
27	Current and Future Treatments for Graves's™ Disease and Graves's™ Ophthalmopathy. <i>Hormone and Metabolic Research</i> , 2018, 50, 871-886.	0.7	27
28	Teriparatide Therapy and Reduced Postoperative Hospitalization for Postsurgical Hypoparathyroidism. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2015, 141, 822.	1.2	26
29	Comparison of long-term antithyroid drugs versus radioactive iodine or surgery for Graves' disease: A review of the literature. <i>Clinical Endocrinology</i> , 2021, 95, 3-12.	1.2	20
30	A Risk Prediction Index for Amiodarone-Induced Thyrotoxicosis in Adults with Congenital Heart Disease. <i>Journal of Thyroid Research</i> , 2012, 2012, 1-7.	0.5	17
31	Amiodarone-Induced Thyrotoxicosis in Adults with Congenital Heart Disease -Clinical Presentation and Response to Therapy. <i>Endocrine Practice</i> , 2014, 20, 33-40.	1.1	17
32	Survey of current approaches to non-diagnostic fine-needle aspiration from solid thyroid nodules. <i>Endocrine</i> , 2015, 49, 745-751.	1.1	16
33	Thyroid dysfunction in adult hematopoietic cell transplant survivors: risks and outcomes. <i>Bone Marrow Transplantation</i> , 2018, 53, 977-982.	1.3	15
34	Rhabdomyolysis after Withdrawal of Thyroid Hormone in a Patient with Papillary Thyroid Cancer. <i>Endocrine Practice</i> , 2008, 14, 1023-1026.	1.1	12
35	Clinical Experience with Rituximab and Intravenous Immunoglobulin for Pretibial Myxedema: A Case Series. <i>Thyroid</i> , 2019, 29, 692-699.	2.4	12
36	Variation in treatment practices for subclinical hypothyroidism in pregnancy: US national assessment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, , .	1.8	11

#	ARTICLE	IF	CITATIONS
37	American Association of Clinical Endocrinology Disease State Clinical Review: The Clinical Utility of Minimally Invasive Interventional Procedures in the Management of Benign and Malignant Thyroid Lesions. <i>Endocrine Practice</i> , 2022, 28, 433-448.	1.1	11
38	Thyrotropin-Axis Adaptation in Aging and Chronic Disease. <i>Endocrinology and Metabolism Clinics of North America</i> , 2005, 34, 973-992.	1.2	9
39	Long-Term Results of Treating With Ethanol Ablation 15 Adult Patients With cT1aNO Papillary Thyroid Microcarcinoma. <i>Journal of the Endocrine Society</i> , 2020, 4, bvaa135.	0.1	9
40	Drivers of the Decision to Biopsy and Follow-Up of Small Suspicious Thyroid Nodules. <i>Endocrine Practice</i> , 2020, 26, 857-868.	1.1	7
41	The "Quiet TED" A Special Subgroup of Thyroid Eye Disease. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2021, Publish Ahead of Print, 551-555.	0.4	5
42	Incidence, risk factors, natural history and outcomes of heart failure in patients with Graves™ disease. <i>Heart</i> , 2022, 108, 868-874.	1.2	5
43	Nonsurgical Management of Thyroid Nodules: The Role of Ablative Therapies. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 1417-1430.	1.8	5
44	Early Hypoparathyroidism Reversibility with Treatment of Riedel's Thyroiditis. <i>Thyroid</i> , 2015, 25, 1055-1059.	2.4	4
45	Effect of thyroid hormone suppression on control of advanced well-differentiated thyroid cancer. <i>Endocrine</i> , 2018, 59, 228-229.	1.1	3
46	Failing Kidneys and Thyroid Dysfunction—An Undesirable Synergy. <i>Mayo Clinic Proceedings</i> , 2018, 93, 555-557.	1.4	3
47	Patient Discomfort in Relation to Thyroid Nodule Fine-Needle Aspiration (FNA) Performed with or without Parenteral and/or Topical Anesthetic. <i>Endocrine Practice</i> , 2020, 26, 1497-1504.	1.1	3
48	Artificial Intelligence Application in Graves Disease. <i>Mayo Clinic Proceedings</i> , 2022, 97, 730-737.	1.4	3
49	In Reply—Ethanol Ablation of Cystic Thyroid Nodules. <i>Mayo Clinic Proceedings</i> , 2019, 94, 171.	1.4	2
50	Thyroid Nodule Size as a Predictor of Malignancy in Follicular and Hurthle Neoplasms. <i>Asian Pacific Journal of Cancer Prevention</i> , 2021, 22, 2597-2602.	0.5	2
51	In Reply—Radiofrequency Ablation Therapy for Large Benign Thyroid Nodules. <i>Mayo Clinic Proceedings</i> , 2018, 93, 1328-1329.	1.4	1
52	Early Thyroidectomy May Decrease Mortality in Amiodarone-Induced Thyrotoxicosis Associated with Systolic Dysfunction. <i>Clinical Thyroidology</i> , 2020, 32, 418-421.	0.0	1
53	MON-623 Higher FT4 Results in Levothyroxine-Treated Patients with Normal TSH Compared to Patients without Thyroid Disease. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.1	1
54	The Learning Curve for Radiofrequency Ablation of Benign Thyroid Nodules. <i>Clinical Thyroidology</i> , 2021, 33, 529-531.	0.0	1

#	ARTICLE	IF	CITATIONS
55	Clinical Management of Thyroid Disease. Mayo Clinic Proceedings, 2010, 85, e85.	1.4	0
56	Multiple Causes for Secondary Hypertension in a Young Female. Nephrology Research & Reviews, 2012, 4, 1-3.	0.2	0
57	Graves' disease-induced complete heart block and asystole. HeartRhythm Case Reports, 2018, 4, 105-108.	0.2	0
58	Tolerogenic Vaccination For Graves' Disease Targeting the Root of the Problem. Clinical Thyroidology, 2019, 31, 372-375.	0.0	0
59	Treatment of Hyperthyroidism Decreases but Does Not Completely Abolish the Increased Risk of Cardiovascular-Related Hospitalization. Clinical Thyroidology, 2019, 31, 49-51.	0.0	0
60	Thermal Ablation Techniques Provide Safe and Effective Treatment of Primary Papillary Thyroid Microcarcinoma. Clinical Thyroidology, 2020, 32, 474-476.	0.0	0
61	Radiofrequency Ablation for Papillary Thyroid Microcarcinoma Is Safe and Effective in Long-Term Follow-up. Clinical Thyroidology, 2021, 33, 121-123.	0.0	0
62	A New Era in Antigen-Specific Immunotherapy: The Promise of Nucleoside-Modified mRNA Vaccines for Autoimmune Thyroid Disease. Clinical Thyroidology, 2021, 33, 154-156.	0.0	0
63	Statin Use Associated with Lower Incidence of Developing Thyroid Eye Disease in Newly-Diagnosed Graves' Disease. Clinical Thyroidology, 2021, 33, 266-268.	0.0	0
64	Thyrotropin-Receptor Antibody Positivity Does Not Correlate with Type 1 or Type 2 Amiodarone-Induced Thyrotoxicosis Phenotype. Clinical Thyroidology, 2021, 33, 388-390.	0.0	0
65	Amiodarone-Induced Thyrotoxicosis. , 2022, , 17-28.		0
66	Disorders of Calcium and Bone Metabolism. , 2013, , 465-472.		0
67	Disorders of the Thyroid Gland. , 2013, , 411-419.		0
68	Natural History, Risk Factors, and Management of Patients with Mild GO. , 2015, , 241-255.		0
69	Graves' Orbitopathy. , 2016, , 348-352.		0
70	Thyroid Disorders. , 2016, , 203-210.		0
71	Calcium and Bone Metabolism Disorders. , 2016, , 149-156.		0
72	The Role of Medical Management for Nodular Hyperthyroidism. , 2017, , 115-132.		0

#	ARTICLE	IF	CITATIONS
73	SAT-LB100 Suspicious Thyroid Nodules: Management Since the Introduction of 2015 ATA Guidelines. Journal of the Endocrine Society, 2019, 3, .	0.1	0
74	OR19-6 A Novel Anti-CD40 Monoclonal Antibody, Iscalimab, Successfully Treats Graves'™ Hyperthyroidism. Journal of the Endocrine Society, 2019, 3, .	0.1	0
75	OR19-3 Utility of the Levothyroxine Absorption Test: The Mayo Clinic Experience. Journal of the Endocrine Society, 2019, 3, .	0.1	0
76	Diagnostic Utility of a New Assay for Thyroid Stimulating Immunoglobulins in Graves' Disease and Thyroid Eye Disease. Thyroid, 2022, 32, 170-176.	2.4	0